Literature DB >> 3784727

[Mesenchymal (non-epithelial) salivary gland tumors. Analysis of 167 tumor cases of the salivary gland register].

G Seifert, H Oehne.   

Abstract

The total material of the Salivary Gland Register (1965-1985) contained 167 mesenchymal tumours with an intra- or paraglandular localisation. This corresponds to 1.5% of all cases of the Salivary Gland Register or to 5% of all salivary gland tumours. Periglandular tumours without relation to the salivary gland tissue, metastatic tumours or malignant lymphomas were not considered in this study. With respect to the localisation, the age and sex distribution and the histopathological classification the following results were obtained: 90% of all mesenchymal tumours were localised in the parotid gland and 10% in the submandibular gland. In lipomas, the percentage of the parotid gland was even 95%; in lymphangiomas, however, it was only 80%. Angiomas occur preferably in the first and second decades and represent in this age period nearly 90% of all mesenchymal tumours. The age peak of lipomas lies in the fifth to sixth decades, whereas neurogenic tumours are distributed relatively equal over the fourth to seventh decades. A sex disposition was seen in lipomas (85% in males), neurinomas (65% in females) and neurofibromas (75% in males). 90% were benign mesenchymal tumours, 10% sarcomas. Within the benign tumours 47.5% were angiomas, 22.5% lipomas, 16% neurogenic tumours and 4% rare benign tumours. In angiomas (79 cases) haemangiomas (50 cases), lymphangiomas (17 cases), mixed haemangiomas and lymphangiomas (9 cases) and haemangiopericytomas (3 cases) could be seen, in neurogenic tumours (27 cases) neurinomas (12 cases), neurofibromas (12 cases) and neurofibromatoses (3 cases), in sarcomas (17 cases) malignant fibrous histiocytomas (5 cases), malignant schwannomas (5 cases), embryonal rhabdomyosarcomas (4 cases) and other rare sarcomas (one case each myxoid liposarcoma, leiomyosarcoma, malignant haemangioendothelioma).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1986        PMID: 3784727

Source DB:  PubMed          Journal:  Laryngol Rhinol Otol (Stuttg)        ISSN: 0340-1588


  8 in total

1.  Hamartomatous angiolipoma of the parotid gland (sialoangiolipoma).

Authors:  Eugenio Maiorano; Saverio Capodiferro; Benito Fanelli; Luca Calabrese; Anna Napoli; Gianfranco Favia
Journal:  Head Neck Pathol       Date:  2008-02-08

2.  Neurofibroma of facial nerve presenting as parotid mass.

Authors:  Arpita Rai; Ansul Kumar
Journal:  J Maxillofac Oral Surg       Date:  2014-08-26

3.  Leiomyosarcoma of the parotid gland: a case report.

Authors:  Stefan Krüger; Konrad Sommer
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-06-15       Impact factor: 2.503

Review 4.  Fat-containing salivary gland tumors: a review.

Authors:  Abbas Agaimy
Journal:  Head Neck Pathol       Date:  2013-07-03

5.  [Solitary intraparotid neurofibroma of the facial nerve. Symptomatology, biology and management].

Authors:  O Fierek; R Laskawi; E Kunze
Journal:  HNO       Date:  2006-10       Impact factor: 1.284

6.  Mesenchymal neoplasms of the major salivary glands: clinicopathological features of 18 cases.

Authors:  Kyung-Ja Cho; Jae Y Ro; Jene Choi; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-10-13       Impact factor: 2.503

7.  Tumor-induced Osteomalacia Caused by a Parotid Tumor.

Authors:  Yuichi Takashi; Yuka Kinoshita; Nobuaki Ito; Manabu Taguchi; Masaaki Takahashi; Naoya Egami; Shogo Tajima; Masaomi Nangaku; Seiji Fukumoto
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

8.  Mesenchymal Neoplasms of Salivary Glands: A Clinicopathologic Study of 68 Cases.

Authors:  Jaylou M Velez Torres; Ernesto Martinez Duarte; Julio A Diaz-Perez; Jason Leibowitz; Donald T Weed; Giovanna Thomas; Zoukaa Sargi; Francisco J Civantos; David J Arnold; Carmen Gomez-Fernandez; Elizabeth A Montgomery; Andrew E Rosenberg
Journal:  Head Neck Pathol       Date:  2021-07-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.